By Michael McGuffin, president, American Herbal Products Association
Questions surrounding the hemp/CBD trade, a recognition of the continued popularity of herbal supplements, and a casting a wary eye toward regulatory creep topped the list of 2019 concerns for the American Herbal Products Association.
An interim federal government funding measure does not include language creating a legal pathway for hemp/CBD products, despite advocacy on the part of stakeholders including lawmakers and trade organizations.
Recent statements and actions by the US Food and Drug Administration (FDA) regarding CBD have spurred four of the dietary supplement industry’s trade association to write Congress urging them to take quick action.
New York State recently put into place regulations that govern hemp cultivation within its borders. In addition, the new law creates a regulatory framework specific to the trade in cannabinoid extracts and finished goods.
It was only a matter of time before the plaintiff’s bar sought to cash in on the legal uncertainty surrounding cannabidiol (CBD), say attorneys. So how might brands defend themselves against the latest wave of lawsuits, which argue that their products...
A recent review of astaxanthin found evidence to support the safety of dosages of 12 mg up to 24 mg a day. But that applies to only to natural astaxanthin, not to the synthetic forms, the authors said.
Hemp-derived CBD brands Charlotte’s Web and Infinite Product Co. have both been hit with proposed class action lawsuits filed in California that allege they misled consumers by marketing their products as dietary supplements when FDA has specifically...